Skip to Main Content

Hello, everyone, and how are you today? We are doing fine, thank you, despite the chilly wintry air enveloping the Pharmalot campus. The short people have left for their respective destinations and the official mascots are snoozing away. Moments like this call for a few cups of stimulation, of course, and we are indulging by toggling between peppermint mocha and butter pecan. Feel free to join us. Meanwhile, here are a few tidbits to help you along. We hope your day is productive and meaningful. And, as always, do keep in touch …

As former Insys Therapeutics (INSY) executives face trials for bribing doctors to boost sales of the Subsys opioid painkiller, the new managers at the company are trying to sell the pain drug to a corporate buyer to raise money, Bloomberg News tells us. And they hope to use the proceeds to pivot out of the opioid business into something slightly less controversial — cannabis-derived drugs. “This pivot may be forced, but CBD and opioid dependence are hot spaces with a lot of interest from investors,” says Curt Wanek, a pharmaceutical equity analyst for Bloomberg Intelligence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!